Eli Lilly (USA) and Innovent Biologics (China) have officially entered their seventh strategic collaboration agreement. This partnership is designed to accelerate the global development and commercialization of innovative therapies in oncology and immunology.
Collaborative Model and Geographical Rights Under the terms of the agreement, Innovent will take the lead during the initial stages of the pipeline. The company will utilize its proprietary antibody technology platforms and clinical execution capabilities in China to head research programs from conception through Phase II clinical trials (Proof-of-Concept).
Commercialization rights are clearly divided by territory:
-
Innovent: Retains all development and commercial rights within Greater China.
-
Eli Lilly: Holds exclusive rights to develop and commercialize these programs in all other global markets.
Financial Structure of the Deal The agreement features a total potential value exceeding $8.8 billion, broken down as follows:
-
An immediate upfront payment of $350 million to Innovent.
-
Success-based milestone payments totaling up to $8.5 billion, contingent upon reaching specific developmental, regulatory, and commercial targets.
-
Innovent is also eligible for tiered royalties based on net sales of products outside of Greater China.
Strategic Vision Innovent leadership emphasized that this alliance goes beyond traditional licensing, creating a “cross-border innovation ecosystem.” By merging Innovent’s agile early-stage discovery engine with Eli Lilly’s extensive global infrastructure, the partnership aims to create a highly efficient model for bringing world-class medical solutions to patients worldwide.
Source: https://www.pharmaceutical-technology.com/news/innovent-lilly-oncology-immunology-medicines/?cf-view